A treatment for neurotrophic keratitis, initially given under expanded access, has been approved for use in European countries. The treatment, a genetically engineered nerve growth factor, has been shown to heal the corneas of affected patients, including children. http://bit.ly/2yjsygw
- Can expanded access give insight into the future success or failure of a new treatment?
- How could research of stem cells improve the delivery of cancer drugs to metastatic tumors?
- Could wider inclusion of minority patients in clinical trials actually lower the cost of healthcare overall?
- New Waiver in IRB Process Speeds FDA Single Patient Expanded Access Approval; Updated Information available on WCGF website.
- How could a new treatment, given previously under expanded access, successfully treat a serious disease of the eye?